GlassScriptPhysician profile
Sarah Bowden
NPI 1962033548
$3,038.88
in general payments reported to CMS, 2019-2025
25 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,312 · 2022: $803 · 2023: $358 · 2024: $243 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.46 | 2021-2025 | |
| Amgen INC. | $430.92 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $404.28 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $267.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.38 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $149.68 | 2021-2023 | Emgality, Jardiance |
| Biohaven Pharmaceuticals, INC. | $147.41 | 2021 | |
| Axsome Therapeutics, INC. | $124.32 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $119.70 | 2021 | |
| Glaxosmithkline, LLC. | $76.06 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $70.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $63.77 | 2022-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $43.61 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $43.03 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.36 | 2023-2024 | Jardiance, Tradjenta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.98 | 2022-2023 | Nexletol |
| Alkermes, INC. | $37.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $32.28 | 2022-2024 | Breztri |
| Pfizer INC. | $26.31 | 2023 | |
| Sumitomo Pharma America, INC. | $18.89 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $17.48 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.96 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $15.53 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.17 | 2023 | Edarbi |
| Endo Pharmaceuticals INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.